Bringing together pharma and healthcare leaders across the Pharmaceutical pipeline to address their needs, to share insights and create debate on crucial topics that influence the future of patient outcomes.
I have participated in several Pharma Integrates and more recently Bio Integrates conferences, both in my capacity as representing a specialist healthcare company and medical research charity. I have always been impressed by the high-profile speakers, the candour with which they shared their experiences, and the professionalism of the conference organisation. This year’s conferences will provide the ideal opportunity to learn about the latest advance in healthcare and to connect and engage with many senior industry colleagues.
Sponsored by
Headline sponsors
Pfizer has a long and proud history of being part of world-class science in the UK. Our site in Sandwich, Kent was one of the world’s first mass-production facilities for penicillin back in the 1950s and continues to be an important location for Pfizer over 65 years later. During the last 20 years, our scientists in Sandwich have discovered new treatments for important disease areas and disorders including heart disease, HIV and migraine.
SK pharmteco is the single market-facing team comprised of SK biotek and AMPAC Fine Chemicals. Creating substantial market synergies in the API CDMO space by combining highly complementary assets and expertise this union enables us to provide the highest-quality services to our customers. SK pharmteco is a wholly owned subsidiary of the South Korean conglomerate SK, a global leader in energy, chemicals and information technology; it is the cornerstone of SK holdings growth strategy.
Valued sponsors and partners
“WE BRING LEADERS TOGETHER, TO DISCUSS, DEBATE AND UNCOVER STRATEGIC SOLUTIONS TO THEIR INDUSTRY CHALLENGES”
In spite of the extraordinary efforts and the significant financial investment behind every drug candidate, only a small fraction will ever make it through clinical trials – less than 10%.
Cardiff, UK – CatSci Ltd, a scientifically led, commercially minded and award-winning innovation partner, today announced partnerships with three UK companies across the pharmaceutical supply chain – M2M Pharmaceuticals (M2M Pharma), New Path Molecular (NPM) and Upperton Pharma Solutions (Upperton).
Nanoform Finland Plc (“Nanoform”), an innovative nanoparticle medicine enabling company will, in the fourth quarter of 2020, start the first ever human trial of a drug candidate nanoformed using Nanoform’s proprietary CESS® technology.
